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The intestinal epithelium deploys multiple defense systems against microbial infection to
sense bacterial components and danger alarms, as well as to induce intracellular signal
transduction cascades that trigger both the innate and the adaptive immune systems,
which are pivotal for bacterial elimination. However, many enteric bacterial pathogens,
including Shigella, deliver a subset of virulence proteins (effectors) via the type III secretion
system (T3SS) that enable bacterial evasion from host immune systems; consequently,
these pathogens are able to efficiently colonize the intestinal epithelium. In this review,
we present and select recently discovered examples of interactions between Shigella
and host immune responses, with particular emphasis on strategies that bacteria use to
manipulate inflammatory outputs of host-cell responses such as cell death, membrane
trafficking, and innate and adaptive immune responses.
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Introduction
Shigella is a causative agent of bacillary dysentery, which ultimately leads to severe bloody and
mucous diarrhea (shigellosis). Most cases of shigellosis occur in developing countries and affect
children under 5 years old. Although antibiotics are the standard care for shigellosis patients,
antibiotic-resistant bacterium is becoming common. Therefore, it is urgently necessary to develop
a safe and effective Shigella vaccine. Shigella have neither adherence factor nor flagella, but they are
capable of efficiently invading the intestinal epithelium. Shigella injects a subset of effectors (secreted
virulence proteins) via a type III secretion system (T3SS) (protein delivery system) into host cells,
allowing the bacterium to invade, multiply within the intestinal epithelium, and subvert cellular
and immune functions during bacterial internalization (1, 2). When Shigella cells are ingested via
the oral route, the bacteria move down to the colon and rectum, and then preferentially enter
the M cells overlying the follicle-associated epithelium of the Peyer’s patches (3, 4) (Figure 1).
Once the bacteria are endocytosed by the M cells, they are transcytosed toward the M cell pocket,
where resident macrophages receive the bacteria. However, Shigella can disrupt the vacuolar mem-
branes, disseminate into the cytoplasm, and multiply therein (5). Bacterial multiplication within
the macrophages results in massive inflammatory cell death (6) (Figure 1). Meanwhile, Shigella
cells that are released from dying macrophages subsequently enter the surrounding epithelium via
the basolateral surface. Upon epithelial cell contact, the bacteria deliver a subset of T3SS effector
proteins that trigger actin rearrangement, promoting bacterial uptake (7). Next, the Shigella cells
are surrounded by a vacuolar membrane, but the bacteria rapidly disrupt this membrane and
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FIGURE 1 | A model for Shigella infection of the intestinal epithelium. A schematic representation of Shigella infection. Bacterial invasion and multiplication
within macrophages and epithelial cells cause subsequent massive inflammatory colitis, termed as shigellosis. Cell-to-cell movement of Shigella occurs at
tricellular junctions via clathrin-dependent endocytosis.
disseminate into the cytoplasm. As Shigella proliferates within
the cytoplasm, it moves by inducing actin polymerization at one
pole of the bacterium, providing the propulsive force required
for inter- or intracellular movement (8–10). Intriguingly, Shigella
cell-to-cell movement preferentially occurs at epithelial tricellular
junctions, where three cells meet (Figure 1). At these positions,
bacteria-containing pseudopodia are engulfed by neighboring
cells via a clathrin-dependent endocytic pathway, resulting in
dissemination of Shigella (11). By repeating these processes, the
bacteria efficiently multiply by constantly renewing their replica-
tive compartment. Thus,multiple infectious events during Shigella
infection, including macrophage cell death, invasion of and mul-
tiplication within epithelial cells, cell-to-cell spreading, demise
of the host epithelium, and alteration of the host inflammatory
response, are major pathogenic events that lead to shigellosis (2)
(Figure 1).
Cell Death
Host-cell death in response to microbial infection is an intrin-
sic immune defense stratagem against microbial intrusion. The
sacrifice of infected cells plays a pivotal role in clearance of
damaged cells, elimination of pathogens, local confinement of
tissue damage and inflammation, and presentation of bacteria-
derived antigens to the adaptive immune system (12). Cell
death induced by bacterial infection can be classified into at
least three types, depending on the type of cell and stage
of infection: apoptosis, necrosis, and pyroptosis. Apoptosis is
a non-inflammatory programed cell death triggered by the
mitochondria-mediated pathway and receptor-mediated path-
way, which eventually induce caspase activation (caspase-2, -3,
-6, -7, -8, -9, and -10), chromatin condensation, cell shrinkage,
plasma membrane blebbing, and cytoplasm retained in apoptotic
bodies. On the other hand, necrosis is an inflammatory form
of cell death characterized by cell swelling, membrane rupture,
and intracellular content leakage. Pyroptosis is pro-inflammatory,
lytic, and programed cell death that is accompanied by activa-
tion of caspase-1 or caspase-11 (human homologs: caspase-4/5)
inflammasomes, leading to the production of IL-1β and IL-18.
When bacteria invade and multiply within host cells, they
release bacterial components [e.g., lipopolysaccharide (LPS)
and peptidoglycan (PGN)] and T3SS components, and further
cause infection-associated cellular damage. These are recog-
nized as pathogen-associated molecular patterns (PAMPs) and
danger-associated molecular patterns (DAMPs) by recognition
receptors, such as toll-like receptors (TLRs), nucleotide-binding
oligomerization domain-like receptors (NLRs), AIM2-like recep-
tors (ALRs), and RIG-like receptors, and trigger host immune
responses against bacterial infection. Upon recognition of these
PAMPs and DAMPs, a subset of NLRs (e.g., NLRP1, NLRP3, and
NLRC4) and ALRs (e.g., AIM2) form inflammasomes, which are
multi-protein signaling complexes composed of NLR/ALR, the
adaptor protein ASC, and inflammatory caspase, such as caspase-
1 (canonical inflammasomes) and caspase-11 (non-canonical
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FIGURE 2 | Shigella manipulates host-cell death. (A) Shigella invasion and
replication in macrophages trigger NLRC4/NLRP3-inflammasomes activation
and pyroptotic cell death. The Shigella T3SS rod component MxiI and needle
protein MxiH trigger NAIP2- and NAIP1-dependent NLRC4-inflammasome
activation, respectively, whereas T3SS effector IpaB-mediated potassium influx
triggers NLRC4-inflammasome activation and ultimately induces pyroptosis.
IpaH7.8 ubiquitinates GLMN, and undergoes proteasome-dependent
degradation, resulting in NLRP3/NLRC4-inflammasome activation and
pyroptosis. (B) Shigella counteracts mitochondrial damage-dependent necrosis
through BNIP3 and CypD by activating the PGN/Nod1/RIP2/NF-κB/Bcl2
pro-survival pathway. Furthermore, Shigella prevents epithelial cell death by
delivering an array of T3SS effectors. PI5P, generated by IpgD, promotes EGFR
activation, which contributes to sustained activation of the PI3K–Akt survival
pathway. IpgD and VirA target Mdm2 and calpain, respectively, to prevent
p53-dependent apoptosis. OspC3 binds to the caspase-4 subunit and inhibits
its activation, thereby blocking caspase-4-dependent inflammatory cell death.
inflammasomes) (13, 14). Inflammasome activation ultimately
results in release of pro-inflammatory cytokines (IL-1β and
IL-18) and induction of pro-inflammatory lytic cell death
(pyroptosis).
When Shigella invade and multiply within macrophages, they
rapidly induce pyroptotic cell death accompanied by NLRP3-
or NLRC4-inflammasome activation, leading to IL-1β and IL-
18 secretion (15–18). T3SS needle or rod components indirectly
activate NLRC4 inflammasomes through members of the NAIP
subfamily of NLRs, which act as direct pathogen recognition sen-
sors and determine the specificity of the NLRC4-inflammasome
for various bacterial ligands. Recent reports have revealed that
human NAIP and mouse NAIP1 bind to Shigella T3SS needle
protein MxiH (19, 20). In addition, NAIP2 binds to the T3SS
inner rod componentMxiI (16, 21) (Figure 2A). Although Shigella
lacks flagella, NAIP5 and NAIP6 specifically activate the NLRC4-
inflammasome in response to other bacterial flagellins (22–25).
Once these NAIP proteins bind to their ligands, they bind to
NLRC4 and induce NLRC4-inflammasome activation and pyrop-
tosis. In addition to bacterial T3SS components, cellular damage
caused by Shigella also triggers inflammasome activation and
pyroptosis. As Shigella cells multiply within macrophages, the
T3SS effector IpaB assembles an ion channel within cell mem-
brane to allow for potassium influx, which is recognized by the
NLRC4-inflammasome and ultimately triggers pyroptosis (26)
(Figure 2A).
As described above, because pyroptosis is accompanied by
inflammation that would limit bacterial infection, it had not
been unclear whether pyroptosis is beneficial for bacterial
infection (27). However, a recent study showed that induc-
tion of inflammasome activation and pyroptosis in infected
macrophages is a Shigella strategy that can promote bacterial
survival and dissemination. Suzuki et al. showed that Shigella
induces rapid macrophage pyroptosis via IpaH7.8, an IpaH family
effector, mediated NLRP3- and NLRC4-dependent inflamma-
some activation (28) (Figure 2A). IpaH family effectors, which
have a novel E3 ubiquitin ligase activity, are widely conserved
among Gram-negative bacterial pathogens, including Shigella,
Salmonella, Yersinia, and Pseudomonas spp. (29). IpaH7.8 targets
GLMN (glomulin/flagellar-associated protein 68), a Cullin-RING
E3 ligase inhibitor, for ubiquitination and undergoes proteasome-
dependent degradation (Figure 2A) (28). Because GLMN acts
as a negative regulator of NLR inflammasomes and pyropto-
sis, degradation of this factor induces inflammasome activation
and pyroptosis. Consistent with results obtained in vitro, mice
intranasally infected with Shigella WT or ∆ipaH7.8/WT com-
plement strains induce more severe inflammatory responses and
elevated numbers of colonized bacteria relative to ∆ipaH7.8 or
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∆ipaH7.8/CA E3 ligase-deficient mutant complemented strains
(28). Therefore, IpaH7.8-mediated macrophage cell death is pre-
requisite for allowing bacteria to escape from macrophages, fur-
ther enter surrounding epithelial cells, and spread to neighboring
cells.
Epithelial Cell Death
When Shigella invade and multiply within epithelial cells, the
cells generate an early genotoxic stress, mitochondrial damage,
oxidative stress, and recognize PAMPs and DAMPs, which could
induce several types of cell death as part of the host defense system
aimed at terminating bacterial infection. However, in contrast
to macrophage infection, Shigella seems to prevent epithelial cell
death until the bacteria have fully multiplied, because it prefers
these cells as replicative niche, spread to neighboring cells, and
evasion of immune cells (30) (Figure 2B). To support this notion,
Shigella has several countermeasures that inhibit epithelial cell
death: (i) prevention of mitochondrial damage, (ii) activation of
cell survival signaling [e.g., phosphoinositide-3 kinase (PI3K)-
Akt and transcription factor nuclear factor κB (NF-κB)], and (iii)
prevention of caspase activation. For example, Shigella prevents
necrotic cell death mediated by mitochondrial damage (through
BNIP3 and CypD) by activating the Nod1–RIP2–NF-κB–Bcl-2
pro-survival pathway (31) (Figure 2B). When Shigella invades
epithelial cells, it delivers the T3SS effector IpgD (a homolog of
Salmonella SopB), a phosphoinositide phosphatase that converts
phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidyli-
nositol 5-phosphate (PI5P), at the bacterial entry site (32). Because
PI plays pivotal roles in actin cytoskeleton rearrangement, elevated
levels of PI5P at the plasma membrane promotes bacterial inva-
sion. Furthermore, IpgD-mediated PI5P is an important factor
involved in cell survival (33). At this step, the PI5P generated
by IpgD contributes to epidermal growth factor receptor (EGFR)
activation, which sustains the PI3K/Akt pro-survival pathway and
thereby contributes indirectly to augmentation of pro-survival
signaling (33, 34) (Figure 2B). A recent report showed that the
early stage of Shigella infection induces genotoxic stress in epithe-
lial cells, followed by p53 pro-apoptotic signaling activation and
induction of apoptosis; however, Shigella promotes p53 degra-
dation and antagonizes the early stage of cell death by deliv-
ering two T3SS effectors, IpgD and VirA (Figure 2B) (35). As
described above, IpgD promotes Akt activation, which in turn
phosphorylates and stabilizes the downstream E3 ubiquitin lig-
ase Mdm2. Activated Mdm2 targets p53 for ubiquitination and
leads to proteasome-dependent degradation, thereby inhibiting
pro-apoptosis signaling by p53. Furthermore, VirA promotes fur-
ther degradation of p53 by activating calpain protease, which is
also important for bacterial invasion. VirA binds to the calpain
inhibitor calpastatin and promotes its degradation, resulting in
degradation of p53 by activated calpain and blocking the p53
pro-apoptotic signaling pathway. Although VirA-mediated cal-
pain activation promotes bacterial entry and prevents the early
stage of apoptosis, sustained calpain activation ultimately induces
necrosis and restricts bacterial proliferation (35). In addition,
Shigella exploits calpain activation and mitochondrial function to
suppress the innate immune response without inducing host-cell
death (see below) (36). These results indicate that Shigella deploys
a sophisticated strategy that controls the delicate balance of host-
cell death until Shigella has succeeded in primary colonization and
proliferation within epithelial cells.
Recent reports have shown that non-canonical caspase-4/-11
inflammasome activation is an essential host defense mecha-
nism of epithelial cells against enteric bacterial pathogens such
as Shigella, Salmonella, and enteropathogenic Escherichia coli
(EPEC). Caspase-4/-11 directly binds to cytoplasmic LPS of
Gram-negative bacterial pathogens and activates caspase-4/-11-
mediated inflammasomes and pyroptosis, ultimately inducing
epithelial cell shedding to eliminate infected cells (37–39). How-
ever, Shigella antagonizes caspase-4-dependent inflammatory cell
death by delivering the T3SS effector OspC3 and promoting
epithelial infection (37). OspC3 deploys a unique mechanism that
specifically targets and inactivates caspase-4, but not caspase-
1 or mouse caspase-11. The C-terminal ankyrin-repeat (ANK)
region of OspC3 interacts with the p19 subunit of caspase-4 and
prevents its activation by inhibiting p19 and p10 dimerization
(Figure 2B). In human epithelial cell lines, the Shigella ∆ospC3
mutant induces early caspase-4-dependent pyroptotic cell death
and increased cytokine production relative to that of WT Shigella.
Of note, the Shigella∆ospC3mutant also exhibited severemucosal
cell death and a reduction in the number of colonizing bacteria in
a guinea pig rectal infection model, indicating the importance of
OspC3-mediated cell death inhibition for bacterial infection (37).
Thus, Shigella delivers a subset of T3SS effector proteins that delay
epithelial cell death until the bacterial cells have fully replicated
and further disseminated into surrounding cells.
Autophagy
Autophagy is an essential cellular catabolic process, which targets
proteins, organelles, and large protein aggregates by sequestering
deleterious cargos within a double-membrane compartment, the
autophagosome. Autophagy also plays a pivotal role as a part of
the innate immune system, by acting as a cytosolic sensor to rec-
ognize DAMPs and PAMPs, and as an “executioner” that engulfs
bacteria in autophagosomes that fuse with lysosomes, ultimately
destroying bacteria within lysosomal compartments.
Shigella enter epithelial cells, disseminate into the cytosol by
disrupting the surrounding phagosomal membrane, and move
into adjacent cells by inducing actin polymerization at one bacte-
rial pole. In Shigella invasion of epithelial cells, Nod1 and Atg16L1
are recruited to the plasma membrane beneath the Shigella entry
site and subsequently trigger autophagy (40). Furthermore, host-
cell vacuolar membrane remnants generated by Shigella are rec-
ognized as DAMPs by galectin-8, and these remnants are also
polyubiquitinated, followed by the recruitment of p62 (ubiquitin
adaptor protein) and LC3 (autophagosome marker), resulting
in autophagic activation (41, 42) (Figure 3). During multiplica-
tion within the cytosol, Shigella outer membrane protein VirG
(IcsA) accumulates at one pole of the bacterial surface. There,
VirG recruits and activates N-WASP, which subsequently recruits
and activates the Arp2/3 complex, thereby inducing actin poly-
merization and bacterial motility within the cell (8–10). At this
stage, VirG is recognized by the host autophagy protein Atg5,
a protein essential for autophagosome maturation, resulting in
Shigella uptake by autophagosomes. However, Shigella prevents
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FIGURE 3 | Shigella prevents autophagic recognition. Shigella prevents
autophagic clearance by evading autophagic recognition. Shigella delivers the
T3SS effector IcsB, which binds to the bacterial outer membrane protein VirG
and prevents Atg5–VirG interaction and ubiquitin recruitment, thereby evading
autophagic recognition. IcsB also recruits Toca-1, and prevents the recruitment
of LC3 to around intracellular bacteria.
autophagic recognition by delivering the IcsB T3SS effector. At an
early stage of infection, IcsB binds to and recruits Toca-1, which is
required for efficient formation of actin polymerization, around
intracellular bacteria, and IcsB–Toca-1 prevents the recruitment
of LC3 (43, 44). Furthermore, at the later stage of infection, IcsB
plays a pivotal role in camouflage against autophagic recogni-
tion (45). IcsB and Atg5 interact with the same region on VirG,
but the affinity of IcsB for VirG is stronger than that of Atg5;
therefore, IcsB competitively inhibits the VirG–Atg5 interaction,
masking the target VirG protein from autophagic recognition
(45) (Figure 3). Consistent with this, the Shigella ∆icsBmutant is
trapped in the autophagosome and delivered for lysosomal degra-
dation (45). Intriguingly, IcsB has cholesterol binding region, and
its ability is involved in evading autophagic recognition without
affecting IcsB–VirG binding (46). In Shigella infection, ubiquitin-
dependent selective autophagy is also triggered, but the bacteria
evade ubiquitin recognition. Although ShigellaWT is not targeted
by ubiquitin, LRSAM1 (a mammalian LRR-containing RING
E3 ligase), which itself acts as a bacterial recognition molecule,
localizes to the Shigella ∆icsB mutant, and LRSAM1-mediated
bacterial ubiquitylation has been observed in vitro (44). LRSAM1
recognition can trigger ubiquitin-dependent selective autophagy,
resulting in restriction of bacterial replication (47). In addition,
another host factor septin, which is GTP-binding protein, assem-
bles at sites of VirG-induced actin polymerization and forms cages
that surrounding bacteria, and prevents inter- and intracellular
movement, thereby targeting by autophagy and restricting bacte-
rial proliferation (48). A recent report showed that the ubiquitin
adaptors p62 and NDP52 target Shigella for autophagy in an
actin polymerization- and septin-dependent manner, and that
the Shigella ∆virG mutant reduces the recruitment of p62 and
NDP52 (49). The Shigella ∆icsB mutant increases septin-cage
formation and the recruitment of ubiquitin, p62, and NDP52.
Therefore, although VirG-mediated actin polymerization is tar-
geted by septin- and ubiquitin-dependent selective autophagy, the
IcsB–VirG interaction prevents the recruitment of ubiquitin, p62,
and NDP52 around bacteria (49) (Figure 3).
Membrane Trafficking
Intracellular trafficking of membranes and proteins is essential
for maintenance of epithelial homeostasis and barrier function,
and also acts as a host defense system against bacterial pathogens.
In eukaryotic cells, intracellular trafficking system can be divided
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into two pathways, endocytosis and the secretory pathway. During
endocytosis, which internalizes extracellular molecules or deliv-
ers plasma membrane proteins to specialized sites, the cargo is
sorted in the early endosome and further transported to Golgi,
endoplasmic reticulum (ER), or late endosomes and lysosome for
degradation, whereas some cargo proteins are transported back
to the plasma membrane via recycling endosomes. On the other
hand, the secretory pathway, which produces molecules such as
antimicrobial peptides, growth factors, cell surface receptors, and
cytokine secretion, transportmolecules from the ER to the plasma
membrane through the Golgi.
Exocytosis, endocytosis, phagocytosis, and cytokine secretion
play essential roles as host defense systems for eliminating invad-
ing bacterial pathogens. However, many intracellular bacterial
pathogens, such as Shigella, Salmonella, and Legionella, hijack
and exploit host intracellular trafficking system to enter host
cells, evade subsequent phagocytic destruction, and establish their
safety replicative niche for their survival and proliferation (7, 50,
51). Shigella enter non-phagocytic cells by delivering a coordi-
nated set of T3SS effector proteins that trigger actin cytoskeleton
or plasma membrane remodeling, and promote subsequent bac-
terial uptake by host cells. Soon after internalization, the bacteria
are engulfed within a membrane-bound vacuole that is derived
from the host plasma membrane. After that, Shigella disrupt and
escape from this vacuole and replicate within the cytoplasm (7).
Vacuolar disruption or modulation by intracellular bacteria is
related to the host membrane trafficking system, which is tightly
regulated by small GTPases of the Rab and ARF families. The
small GTPases act as molecular switches that cycle between the
GTP-bound active form and GDP-bound inactive form, catalyzed
by two classes of regulatory proteins, guanine nucleotide exchange
factors (GEFs) and GTPase-activating proteins (GAPs). GEFs
exchange GDP for GTP to activate GTPases, whereas GAPs inac-
tivate GTPases by promoting hydrolysis of GTP to GDP (52).
Rab and ARF GTPases play an important role in resisting bac-
terial infection, such as secretion of cytokines and antimicrobial
peptides, maintenance of epithelial barrier integrity, and matu-
ration of phagosomes into lysosomes to degrade entrapped bac-
teria. Therefore, Shigella target Rab GTPases and interfere with
host membrane trafficking by delivering T3SS effector proteins
(Figure 4).
In Shigella infection, the endocytic pathway is essential event
for bacterial invasion, vacuolar rupture, and spread to neighbor-
ing cells. Using a high-content siRNA screening, Mellouk et al.
recently demonstrated that Shigella targets and recruits Rab11, a
component of host recycling endosomes, to disrupt the vacuole
and efficiently escape from it by delivering the IpgD effector
(53) (Figure 4). As described before, IpgD is a phosphoinositide
phosphatase that produces PI5P, which is important for vesicular
trafficking. In cells infected with Shigella ∆ipgD or phosphatase-
inactive ∆ipgD/ipgD C438S complemented mutant, Rab11 is not
recruited to the site of bacterial invasion, and vacuolar rupture is
delayed; however, this deficiency is rescued by the complemen-
tation of ∆ipgD/ipgD WT or WT Shigella infection, highlighting
the requirement for the phosphoinositide phosphatase activity
of IpgD. Furthermore, vacuole disruption by Shigella is delayed
in Rab11 knockdown epithelial cells without affecting bacterial
FIGURE 4 | Shigella alters host intracellular trafficking. Shigella exploits
and alters intracellular trafficking to manipulate the host defense system. PI5P
produced by IpgD recruits Rab11 to the bacterial entry site and promotes
vacuolar membrane disruption. Production of PI5P by IpgD further relocates
EGFR in early endosomes, resulting in blocking lysosomal degradation of
EGFR and sustaining PI3K–Akt survival pathway. VirA and IpaJ target and
inactivate Rab1 and ARF1, respectively, thereby preventing intracellular
trafficking and Golgi disruption. IpaB binds to and relocates cholesterol from
Golgi to bacterial entry sites, resulting in Golgi fragmentation.
invasion (53). Therefore, Shigella targets Rab11 to disrupt the vac-
uole and allow bacterial escape into the cytoplasm and promote
further bacterial replication and dissemination.
In addition, as mentioned above briefly, IpgD subverts host
intracellular trafficking to promote host-cell survival for bacterial
prolonged colonization (34). The production of PI5P by IpgD at
bacterial entry sites recruits active EGFR, which is required for
the PI3K–Akt survival signaling pathway. An elevated level of
PI5P at the plasma membrane, due to the activity of IpgD, alters
EGFR trafficking and relocates it to early endosomes from late
endosomes or lysosomes, thereby blocking lysosomal degrada-
tion of EGFR and sustaining EGFR–PI3K–Akt survival signaling
activation (34) (Figure 4).
The Golgi apparatus is a central organelle involved in protein
or lipid transport in eukaryotic cells. The Golgi processes and
sorts proteins made by the ER, and transport them to various
destinations, such as the plasma membrane and lysosome. There-
fore, defects in Golgi function result in the loss of intracellu-
lar trafficking, including secretion of antimicrobial peptides and
cytokines, and transport of epithelial junction proteins that are
essential for epithelial barrier function against bacterial infection.
Intriguingly, Shigella disrupts the Golgi apparatus by inhibiting
vesicle trafficking in infected epithelial cells in a T3SS-dependent
manner. Of note, three Shigella effectors, VirA, IpaJ, and IpaB, play
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important roles in disrupting theGolgi apparatus by targeting host
intracellular trafficking (Figure 4).
Recent reports have shown that VirA and IpaJ, which have spe-
cific enzymatic activities targeting Rab and ARF GTPases, respec-
tively, dampen host antibacterial defense systems by inhibiting
the host secretory pathway. VirA (a homolog of EPEC EspG),
which has TBC (homologous catalytic domain of GAP for Rab
GTPase)-like GAP activity, preferentially targets and catalyzes
GTP hydrolysis in Rab1, which localizes in the ER and mediates
ER-to-Golgi trafficking (54). VirA inactivates Rab1, inhibits ER-
to-Golgi transport of Rab1-containing vesicles, and disrupts the
Golgi apparatus in host epithelial cells (Figure 4). Because Rab1
is important for autophagosome formation, Rab1 inactivation by
VirA counteracts antibacterial autophagy. Of note, infection by a
Shigella ∆virA mutant or GAP-inactive ∆virA/virA-RQ comple-
mented mutant increases autophagosome formation and reduces
the number of colonizing bacteria relative to that of WT Shigella
in human epithelial cell lines. Thus, TBC-like GAP activity of
VirA contributes to bacterial escape from autophagy and intracel-
lular survival by blocking intracellular trafficking through Rab1
GTPase inactivation (54).
A bioinformatics approach revealed that IpaJ belongs to the
cysteine protease family, whose members have Cys–His–Asp
catalytic triad residues (55, 56). Further yeast genetic screen-
ing and mass spectrometry analysis demonstrated that IpaJ
specifically cleaves the N-myristoylated glycine from ARF1
(Figure 4). N-myristoylation is an essential fatty-acid modifica-
tion that is involved in protein localization, signal transduction,
autophagosome maturation, and organelle function. Because N-
myristoylation of ARF1 is essential for binding to the Golgi mem-
brane, IpaJ-mediated cleavage induces the release of ARF1 from
Golgi and its disruption, thereby inhibiting intracellular traffick-
ing, including cytokine secretion and signal transduction (55, 56).
Another effector, IpaB, also disrupts the Golgi apparatus by
targeting lipid trafficking, and thereby reduces epithelial barrier
function. IpaB binds to and redirects cholesterol at the bacterial
entry site from the Golgi apparatus, which depletes the lipid
of Golgi and induces its fragmentation (Figure 4). The Golgi
apparatus fragmentation further induces tubulation of the Rab11-
positive compartment and reorganizes the recycling endosome,
which is involved in trafficking of E-cadherin to adherence junc-
tion, resulting in epithelial junction disruption (57).
As described above, membrane and protein trafficking, such
as the phagosome component, epithelial barrier components,
antimicrobial peptides, cytokines, and cell surface receptors, is
a major host defense system against bacterial infection. There-
fore, Shigella blocks and alters host intracellular trafficking by
delivering subsets of effectors that promote infection.
Manipulation of Host Innate Immunity
Once Shigella invades and replicates within host cells, the innate
immune system quickly senses PAMPs or DAMPs, and transmits
various alarm signals to the rest of the immune system, and ulti-
mately triggers inflammation. Inflammation, which is accompa-
nied by inflammatory cytokine secretion, neutrophil recruitment,
and massive tissue destruction, is the hallmark of the host innate
immune response that eventually restricts and eliminates bacterial
infection. However, many bacterial pathogens, including Shigella,
deliver a subset of T3SS effectors that manipulate host innate
immune responses, thereby promoting bacterial colonization and
survival (2) (Figure 5).
ATP Release
During bacterial infection, various molecules are released from
damaged or stressed cells as DAMPs (e.g., ATP, uric acid,
and membrane remnants), which trigger inflammatory immune
responses. For example, infection of intestinal epithelial cells
with enteric bacterial pathogens, such as Shigella, Salmonella,
andEPEC, induce connexin hemichannel-dependentATP release,
which acts as an endogenous danger alarm against bacterial infec-
tion and triggers inflammatory responses (58). Hemichannel-
dependent ATP release is a common host defense system against
enteric bacterial infection. To counteract ATP-dependent inflam-
mation, Shigella blocks ATP release by delivering IpgD to epithe-
lial cells. IpgD blocks hemichannels and prevents ATP release
through production of PI5P, which regulates hemichannel open-
ing, thereby dampeningATP-dependent inflammation (Figure 5).
Consistent with this, in both in vitro and in vivo infections, the
Shigella ∆ipgDmutant causes elevated ATP release, severe intesti-
nal inflammation, and mucosal damage, illustrating the key role
of IpgD in preventing ATP-dependent inflammation (58).
Manipulation of NF-κB Signaling
During bacterial infection, the transcription factor NF-κB, the
master regulator of pro-inflammatory cytokines, plays a major
role inmediating an inflammatory signaling pathway that triggers
a wide range of host inflammatory responses. In response to
bacterial infection, several intracellular and extracellular stim-
uli activate signal transduction cascades, and NF-κB is translo-
cated into the nucleus, where it promotes the transcription of
target genes (59). In particular, ubiquitination of signaling fac-
tors is prerequisite for regulation of NF-κB activity; therefore,
many bacterial pathogens, including Shigella, inhibit NF-κB acti-
vation by targeting signaling factors and altering signal trans-
duction, thereby dampening inflammation, in order to promote
infection (60).
Invasion of epithelial cells by Shigella produces membrane
ruffles by remodeling the actin cytoskeleton around the bac-
terial entry site. Aberrant membrane ruffles, which protrude
from the bacterial entry site and are accompanied by diacyl-
glycerol (DAG) production, are sensed as DAMPs by the host
innate immune system and trigger the activation of the DAG-
CBM (CARMA-BCL10-MALT1)-TRAF6-NF-κB pathway. How-
ever, Shigella delivers OspI via the T3SS into the host cells;
this factor targets and deamidates UBC13 (converts Gln-100
to Glu-100), an E2 required for TRAF6 E3 activity, resulting
in abolition of its E2 activity and thereby interfering with the
DAG–CBM–TRAF6–NF-κB pathway (61) (Figure 5).
Following membrane ruffling, Shigella-mediated vacuolar
membrane ruptures are also recognized as DAMPs, trigger-
ing an additional alarm-signaling pathway via recruitment and
activation of PKC, ultimately leading to the activation of the
PKC–NF-κB pathway. To counteract PKC–NF-κB activation,
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FIGURE 5 | Shigella manipulates the host innate and adaptive immune
response. Shigella manipulates host inflammatory responses by delivering a
subset of T3SS effectors, including IpgD, OspI, OspG, OspF, and IpaH. PI5P,
generated by IpgD, prevents ATP release-dependent inflammation through
hemichannels. OspG binds to ubiquitin and ubiquitinated E2 proteins and
prevents IκBα ubiquitylation, which is required for NF-κB activation. OspI
deamidates and inactivates Ubc13, resulting in inhibition of TRAF6
ubiquitination. IpaH0722 and IpaH9.8 target TRAF2 and NEMO, respectively, for
ubiquitination, and undergo proteasome degradation. In addition, IpaH9.8
further targets U2AF35, preventing its participation in the splicing reaction via an
unidentified bacterial factor, Shigella induces calpain-dependent BID activation,
which, in turn, releases mitochondrial SMAC to antagonize XIAP-mediated
inflammation. IpgD-mediated hydrolysis of PIP2 inactivates ERMs of T cells,
which crosslink actin filaments with the plasma membrane, thereby preventing
T cell migration. Shigella induces B cell death in both invaded and non-invaded
cells. In non-invaded cells, the T3SS needle-tip protein IpaD interacts with TLR2
on B cells and triggers mitochondrial damage, which eventually induces
apoptosis.
Shigella delivers IpaH0722, one of the IpaH family of E3 ubiqui-
tin ligase effectors. IpaH0722 dampens the acute inflammatory
response by ubiquitination of TRAF2, a molecule downstream
of PKC, thereby preferentially inhibiting PKC-mediated NF-κB
activation (62) (Figure 5).
During Shigella invasion of epithelial cells, Nod1 recognizes
PGNs released from Shigella as PAMPs, triggering theNod1–RIP2
pathway and activating the downstream mitogen-activated pro-
tein kinase (MAPK) andNF-κB signaling pathways. Shigelladeliv-
ers IpaH9.8, an IpaH family E3 ubiquitin ligase effector, which
preferentially prevents the Nod1-dependent NF-κB activation.
IpaH9.8 interacts with NEMO/IKKγ, an essential component of
the IKK kinase complex, and targets NEMO for ubiquitination.
IpaH9.8 also interacts with ABIN-1, an ubiquitin-binding adap-
tor protein, to further promote polyubiquitylation of NEMO.
Ubiquitinated NEMO by IpaH9.8 subsequently leads to protea-
somal degradation, thereby diminishing NF-κB activation (63)
(Figure 5). The activity of this E3 ligase effector during Shigella
infection contributes to bacterial colonization in a mouse lung
infection models (63).
Upon Nod1 activation, the X-linked inhibitor of apoptosis
protein (XIAP) plays a crucial role in activating Nod1-dependent
inflammatory responses. XIAP interacts with RIP2 and facili-
tates NF-κB activation, ultimately leading to pro-inflammatory
gene transcription. A recent report showed that Shigella evades
XIAP-mediated inflammation by actively releasing mitochondrial
SMAC (36). Shigella infection triggers calpain activation and pro-
cesses and activates BH3-only protein BID, which then translo-
cates to the mitochondria and induces the release of SMAC.
Released SMAC binds to XIAP, and inhibits XIAP-mediated NF-
κB activation without inducing mitochondrial damage or cell
death (Figure 5). Although it remains unknown whether BID-
mediated release of SMAC by Shigella depends on a T3SS effector,
Shigellauniquely exploitsmitochondrial function to block the host
innate immune response while avoiding cell death (36).
In addition, Shigella delivers another effector, OspG, which
shares sequence similarity with mammalian serine/threonine
kinases and inhibits NF-κB activation (64). OspG binds to ubiqui-
tin and ubiquitinated E2s, which are required for phospho-IκBα
ubiquitination by an E3 ligase such as SCFβ-TrCP, and formation
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of this OspG–E2-ubiquitin complex promotes OspG kinase activ-
ity and increases the prevention of NF-κB activation (64–67)
(Figure 5).
Epigenetic Regulation of Immune Gene
Expression
Because the host transcriptional program plays a pivotal role
in triggering inflammation and eliminating bacterial infection,
Shigella overcomes this defense mechanism by delivering a sub-
set of T3SS effector proteins that regulate gene expression and
counteract host immune responses. In addition to interfering
with NF-κB signaling, as described above, Shigella hacks the host
immune responses by reprograming the host epigenome to pro-
mote infection. The T3SS effector OspF (homolog of Salmonella
SpvC and Pseudomonas syringae HopAl1), which has a unique
phosphothreonine lyase activity, translocates into the nucleus of
epithelial cells, where it irreversibly dephosphorylates and inac-
tivates MAPKs (Erk and p38) through beta-elimination of the
phosphate group (68, 69). Inactivation of MAPK by OspF further
blocks downstream phosphorylation of histone H3 at Ser10 at
the promoters of a subset of innate immune genes, such as IL-
8, and promotes chromatin condensation, resulting in repression
of transcription by masking NF-κB binding sites (68) (Figure 5).
In addition to histone modification, OspF also alters the activ-
ity of the chromatin reader heterochromatin protein 1 (HP1)
and represses host gene expression during Shigella infection (70).
Although phosphorylated HP1γ at Ser83 proteins positively reg-
ulate euchromatin (a transcriptionally active state) and activate
transcription, OspF inactivates Erk and consequently reduces the
activity of the downstream kinase MSK1, a kinase for HP1γ at
Ser83. As a result of HP1γ dephosphorylation, HP1γ dissoci-
ates from sites of transcriptional activation at OspF-target genes
such as IL-8 (Figure 5). Consistent with this, the Shigella ∆ospF
mutant increased the level of HP1γS83 phosphorylation relative
to WT Shigella-infected cells (70). Therefore, OspF manipulates
host transcriptional response via two epigenetic modifications: (i)
decreasing the level of phosphorylated histoneH3, and (ii) altering
the activity of HP1 through dephosphorylation of MAPK, which
contributes to downregulation of host inflammatory responses.
In addition to OspF, Shigella delivers IpaH9.8 to regulate pro-
inflammatory gene expression. IpaH9.8 is translocated into the
nucleus of epithelial cells, where it binds to U2AF35, an mRNA
splicing factor, and inhibits the U2AF35-dependent splicing reac-
tion, enabling the bacterium to dampen expression of numerous
genes, including some that encode pro-inflammatory cytokines
and chemokines (71) (Figure 5).
Manipulation of Host Adaptive Immunity
Manipulation of the host innate immune response by Shigella is
a pivotal survival strategy for promoting infection; however, the
interactions between Shigella and adaptive immune response, such
as T and B lymphocytes, have not been thoroughly investigated.
One prominent issue is the lack of appropriate animal infec-
tion models that mimic human intestinal infection. Until now,
however, several studies have proven the importance of adaptive
immunity against Shigella infection using a mouse pulmonary
infection model that mimics the acute inflammation that occurs
during shigellosis. Mice that are genetically deficient in B, T,
and NK cells are much more susceptible to Shigella infection
than WT mice, and T and NK cells play critical roles in clearing
Shigella (72). Additional studies have shown that CD4+ T helper
17 (Th 17) cells, which are predominantly primed in response to
Shigella, produce IL-17A and eventually restrict secondary Shigella
infection, indicating the involvement of Th17 cells in adaptive
immunity against Shigella infection (73). By contrast, antigen-
specific CD8+ T cells, which are usually required for adaptive
immunity against cytosolic bacterial infection, are not primed and
involved in adaptive immunity against Shigella infection (74). As
the precise role and the importance of adaptive immunity against
Shigella infection have been revealed, several recent studies have
shown that host adaptive immunity is targeted and subverted by
Shigella T3SS effectors (Figure 5).
T cell migration and activation are key events in the induc-
tion of antibody- and cell-mediated immune responses against
bacterial infection. Recently, the Phalipon group investigated
the interaction between T cells and Shigella using in vitro and
in vivo approaches, and demonstrated that Shigella interferes
with adaptive immune responses by targeting T cells. They also
found that Shigella invades activated CD4+ T cells and inhibit
chemoattractant-mediated T cell migration by delivering IpgD
(75). T-lymphocyte migration toward a chemoattractant depends
on the membrane cytoskeleton crosslinkers proteins ERM (ezrin,
radixin, and moesin), which are tightly converted between the
active and inactive conformation by the concentration of PIP2 at
the plasma membrane. Because IpgD is phosphoinositide phos-
phatase, it subsequently hydrolyzes and decreases the concen-
tration of PIP2 at the plasma membrane, thereby inactivating
ERM (Figure 5). In addition, Shigella impairs CD4+ T cell
dynamics within lymph nodes, where adaptive immunity is ini-
tiated, in the mouse infection model (76). Therefore, Shigella
targets T-lymphocytes and inhibits their migration by deliver-
ing the T3S effector IpgD, thereby interfering with adaptive
immunity.
B lymphocytes are key players in antibody-mediated immunity,
and they produce and secrete cytokines that contribute to the
antibody-independent immune response against bacterial infec-
tion. However, massive T- and B-cell deaths are observed in
rectal biopsies of Shigella-infected humans, indicating that Shigella
impairs B cell-mediated immunity (77). To support this notion,
a recent report showed that Shigella targets B cells and induces
cell death in both Shigella-invaded and non-invaded cells (78).
Shigella invades B cells and replicates intracellularly, resulting in
B cell death. Furthermore, Shigella induces B cell apoptosis via
the T3SS needle-tip protein IpaD. IpaD binds to TLR2 on B cells
and triggers the loss of mitochondrial dysfunction and apoptotic
cell death signaling in non-invaded B cells, eventually helping
the bacterium to avoid antibody-mediated immune responses
(78) (Figure 5). Therefore, Shigella targets T and B cells and
manipulates adaptive immunity against Shigella infection, thereby
preventing antibody-mediated lasting immunity and promoting
bacterial infection.
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Conclusion
Although bacterial infection elicits host defense systems
that would restrict and eliminate bacteria, many bacterial
pathogens have evolved excellent strategies to manipulate host
immune responses and enable bacterial colonization. Here, we
review the current understanding of how Shigella manipulates
host immune responses, focusing specifically on T3SS effector-
mediated interference with host signaling transduction cascades,
alteration of membrane trafficking, and modulation of host-cell
death. Our understanding of themolecular basis of the interaction
between bacterial effectors and host immune systems has
advanced greatly during the past decade. Although accumulating
evidence has revealed the importance of manipulation of the
host immune system during bacterial infection, our knowledge
of bacterial strategy is still in its infancy. Although approximately
50 T3SS effectors of Shigella are currently recognized, we have
only elucidated the molecular function of one-third of them.
As has been shown for other bacterial pathogens, the effector
activity and strategies described above are not unique to Shigella,
but are instead shared as common strategies by many bacterial
pathogens. Therefore, the discovery of new Shigella strategies
that manipulate the host immune system will not only provide
a new understanding of how bacteria subvert the host immune
systembut also facilitate development of new types of antibacterial
drugs that target bacterial effectors and bacterial live vaccines to
overcome bacterial infections.
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